|
December 2008
|
Acquisition of Protherics PLC
|
|
November 2008
|
BGC945, a targeted developmental cancer treatment, is licensed to Onyx Pharmaceuticals, Inc
|
|
June 2008 |
Protez Pharmaceuticals, founded in 2003 by BTG and its management team to discover and develop novel antibiotics, is acquired by Novartis
|
|
October 2007 |
BTG’s licensee Tolerx, Inc forms a collaboration with GlaxoSmithKline to develop TRX4 for a range of auto-immune disorders
|
|
September 2007 |
Genzyme corporation, BTG’s licensee, starts Phase III trials of Campath® in multiple sclerosis
|
|
September 2007 |
IP for CoVaccine HT™ licensed to Nobilon, a division of Schering Plough, for use in its flu vaccines
|
|
December 2006 |
Positive results from the EU Phase III trial of Varisolve®, under development as a treatment for varicose veins, published in Phlebology
|
|
February 2006 |
BTG licenses novel compounds for Alzheimer’s Disease to Senexis Limited and co-invests in Senexis alongside the Wellcome Trust
|
|
December 2005 |
Development and commercialisation agreement with AstraZeneca for CytoFab™, under development to treat severe sepsis
|
|
May 2005 |
BTG announces plans to divest physical sciences interests and to focus solely on life sciences
|
|
2003 |
Nobel Prize for Medicine awarded to inventor of MRI, a technology first licensed by BTG in the 1980s
|
|
2002 |
US launch of DigiFab™, a treatment for the toxic effects of over dosage with the heart drug digoxin
|
|
2001 |
US approval of Campath® and EU approval of MabCampath® for chronic lymphocytic leukaemia
|
|
2001 |
US launch of CroFab™, the first new rattlesnake anti-venom on the US market in 50 years
|
|
1999 |
BTG forms Provensis Ltd to develop and commercialise Varisolve®, a novel treatment for varicose veins
|
|
1999 |
Protherics PLC formed from the merger of Proteus International plc and Therapeutic Antibodies Inc.
|
|
1997 |
BeneFIX® recombinant Factor IX treatment for haemophilia B launched in the US
|
|
1995 |
BTG plc is listed on the London Stock Exchange
|
|
1992 |
BTG is privatised
|
|
1981 |
BTG is formed from the merger of the National Research & Development Council and the National Enterprise Board
|
|
1970s |
Patenting/development of: cholesterol assay tests; MRI; Oxford three-part knee
|
|
1960s |
Patenting/development of: continuously variable transmission; cephalosporin antibiotics; pyrethrin insecticides
|
|
1950s |
Patenting of interferon
|
|
1948 |
National Research Development Corporation founded by UK government to commercialise publicly funded research
|